ArticleOral diseases2025
Temporomandibular Disorders in Brain Injury Patients and Diagnostic Accuracy of the Assessment Tools.
Article in Oral diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic accuracy of the Fonseca anamnestic index for temporomandibular disorders: a systematic review and meta-analysis.Head & face medicine · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectivesTo evaluate the presence, severity and progression of temporomandibular disorders (TMD) in acquired brain injury (ABI) population and determine the diagnostic accuracy of 3Q/TMD and Fonseca Anamnestic Index (FAI) against the gold standard, Diagnostic Criteria for TMD (DC/TMD).
methodsABI individuals were assessed using 3Q/TMD and FAI at admission (n = 73) and Week 4 (n = 52), while DC/TMD was conducted only at Week 4. Diagnostic accuracy, sensitivity and specificity of 3Q/TMD and FAI were calculated against DC/TMD.
resultsTMD was detected in 66.0% (3Q/TMD) and 27.8% (FAI) at admission, with mild (75%) to moderate (25%) severity which was mostly pain-related. TMD frequency decreased to 11.3% (3Q/TMD) and 17.3% (FAI) by Week 4. Accuracy rates were 0.82 for 3Q/TMD and 0.83 for FAI. Sensitivity was 0.33 (3Q/TMD) and 0.50 (FAI), while specificity was high at 0.93 (3Q/TMD) and 0.90 (FAI).
conclusionsTMD presence was higher in an ABI population compared to the general population however the frequency decreased over time. The high specificity and accuracy of 3Q/TMD and FAI indicate their potentials as screening tools but their low sensitivity limits their effectiveness in identifying all TMD cases. Patients with ABI should be assessed for TMD as part of their comprehensive care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.